Back

Drug Pricing Summary

NADAC

$0.0439 - $1.4793

VA FSS

$0.3230 - $8.0000

Drug Product Pricing

Product $/unit Ctry. List Type
Product (units) Manufacturer
azelastine hydrochloride 0.5 mg / 1 mL (1 mL DROPS) $1.4793 NADAC generic
  • Azelastine Hydrochloride Ophthalmic Solution 0.05% (1)
  • Alembic Pharmaceuticals Inc.
    azelastine hydrochloride 0.5 mg / 1 mL (1 mL DROPS) $8.0000 VA FSS
  • AZELASTINE HYDROCHLORIDE (6)
  • Golden State Medical Supply, Inc.
  • Azelastine Hydrochloride (6)
  • Golden State Medical Supply, Inc.
    azelastine hydrochloride 137 ug (SPRAY) $0.3383 VA FSS
  • Azelastine Hydrochloride (30)
  • Golden State Medical Supply, Inc.
    azelastine hydrochloride 137 ug (SPRAY) $0.4337 VA FSS
  • Azelastine Hydrochloride (30)
  • Mylan Pharmaceuticals, Inc.
    azelastine hydrochloride 137 ug / 0.137 mL (0.1 mL SPRAY) $0.0439 NADAC generic
  • AZELASTINE HYDROCHLORIDE (7.3)
  • Breckenridge Pharmaceutical, Inc.
    azelastine hydrochloride 1.5 mg / 1 mL (1 mL SPRAY) $0.7692 NADAC generic
  • Azelastine Hydrochloride (1)
  • Hi-Tech Pharmacal Co., Inc.
    azelastine hydrochloride 1.5 mg / 1 mL (1 mL SPRAY) $1.8363 VA FSS
  • Azelastine Hydrochloride (30)
  • Golden State Medical Supply, Inc.
    azelastine hydrochloride 1 mg / 1 mL (1 mL SPRAY) $0.3203 NADAC generic
  • Azelastine Hydrochloride (1)
  • Amneal Pharmaceuticals LLC
    azelastine hydrochloride 1 mg / 1 mL (1 mL SPRAY) $0.3230 VA FSS
  • Azelastine Hydrochloride (30)
  • AvKare, LLC
    azelastine hydrochloride 205.5 ug (SPRAY) $0.7233 VA FSS
  • Azelastine Hydrochloride (30)
  • Mylan Pharmaceuticals, Inc.
    azelastine hydrochloride 205.5 ug (SPRAY) $3.5447 VA FSS
  • Azelastine Hydrochloride (30)
  • AvKare, LLC

    Note: This drug pricing data is preliminary, incomplete, and may contain errors.

    Feedback

    Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

    Report issue